Press release
Diabetic nephropathy Therapeutic Pipeline Market Review, H1 2017
SummaryDiabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1119729-diabetic-nephropathy-pipeline-review-h1-2017
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 15, 6, 30, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content: Key Points
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Diabetic Nephropathy - Overview 9
Diabetic Nephropathy - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Diabetic Nephropathy - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Diabetic Nephropathy - Companies Involved in Therapeutics Development 31
AbbVie Inc 31
Allergan Plc 31
Antisense Therapeutics Ltd 32
Aptevo Therapeutics Inc 32
Araim Pharmaceuticals Inc 33
Arena Pharmaceuticals Inc 33
Astellas Pharma Inc 34
AstraZeneca Plc 34
Bayer AG 35
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/1119729-diabetic-nephropathy-pipeline-review-h1-2017
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic nephropathy Therapeutic Pipeline Market Review, H1 2017 here
News-ID: 527642 • Views: …
More Releases from Diabetic nephropathy Market
Diabetic Nephropathy market 2020 | Mitsubishi Tanabe Pharma Corporation, Novarti …
Diabetic nephropathy is known as the most significant impediment occurring in the kidney glomerulus which render the patient morbid or even worse in majority of the cases. Characterized by macroalbuminuria, diabetic nephropathy is diagnosed when more than 300 milligrams of albumin are present in the urine in a day. The global market for diabetic nephropathy was valued at US$ 2,262.2 million in 2014. Registering a steady CAGR of 5.6%, the…
More Releases for Metabolic
Comprehensive Metabolic Panel Testing Market Size
The findings reviewed by GME stated that the Global Comprehensive Metabolic Panel Testing Market will grow from USD 11.5 billion in 2021, to USD 13.8 billion in 2026 with a CAGR value of 7.5%. Factors like the rising prevalence of chronic diseases, increasing prevalence of Covid-19 and increasing patients, technological advancements, increasing disposable income, growing geriatric population, emphasis on early diagnosis and treatment are expected to support the growth of…
Therapeutic Proteins for Metabolic Disorders Treatment Market is Driven by Incre …
Therapeutic Proteins for Metabolic Disorders Treatment Market: Introduction
Therapeutic proteins are proteins which are engineered in a laboratory for pharmaceutical use. Therapeutic proteins are used as a personalized treatment approach which supports a precisely targeted therapeutic process by making up for the deficiency of an essential protein.
Therapeutic proteins are deliberately adjusted to increase their clinical potential which is followed by enhancements derived from protein or glycol engineering, Fc fusion, or conjugation…
Inherited Metabolic Disorders Market Comprehensive Survey 2025
Global Inherited Metabolic Disorders Market: Overview
Globally, IMD affects nearly one in every 2,500 to 5,000 individuals with nearly 300 to 600 new cases found in the U.K., according to Public Health Genetics U.K. The specificity and high risk affinity of IMD varies from disorder to disorder, with some disorders like familial cylomicronemia being closely associated with Caucasians and others like porphyria being recoded largely among African Americans. These metabolic…
Metabolic Testing Market Opportunity Analysis, 2018-2026
Metabolic testing involves assessment of health and wellbeing of an individual. Metabolic testing equipment are used to screen organ functions and disease condition such as liver diseases, diabetes, kidney diseases, and cardiovascular diseases. Metabolic syndrome is a group of metabolic disorders such as high blood pressure with high fasting glucose levels and abnormal obesity. Metabolism pattern and metabolic capacity is determined with the help of metabolic testing for management of…
Inherited Metabolic Disorders Market Felicitous over 2025
Global Inherited Metabolic Disorders (IMD) Market: Snapshot
Inherited metabolic disorders (IMD), as the name suggests, are genetic conditions resulting in metabolism issues. The root cause behind maximum cases of inherited metabolic disorders (IMD) is a gene mutation that probably happened a lot many generations back. The mutation in the gene is carried through the generations.
Treatment of inherited metabolic disorders (IMD) consists of dietary supplementation, dietary restrictions, drugs that thwart or regulate…
Inherited Metabolic Disorders Market Current Trends by 2025
Global Inherited Metabolic Disorders (IMD) Market: Snapshot
Inherited metabolic disorders (IMD), as the name suggests, are genetic conditions resulting in metabolism issues. The root cause behind maximum cases of inherited metabolic disorders (IMD) is a gene mutation that probably happened a lot many generations back. The mutation in the gene is carried through the generations.
Treatment of inherited metabolic disorders (IMD) consists of dietary supplementation, dietary restrictions, drugs that thwart or regulate…
